Aortic Diseases Clinical Trial
Official title:
Post-market Study on Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases
The objective of this study is to assess the benefits of endovascular technique in terms of efficacy and safety of Valiant Thoracic Stent Graft with the Captivia Delivery System in the treatment of thoracic aortic disease, in a cohort of patients representative of the population treated under real-life conditions of use in France for up to 5 years.
Data regarding the use under routine practice of thoracic aortic stent grafts in France are expected by the French National Authority for Health (HAS). Therefore, in its opinion report from December 22, 2009, HAS makes the maintenance of reimbursement approval of each stent graft dependent on the presentation of results of a specific follow-up study carried out in a cohort of patients representative of the French population treated under real-life conditions of use. This prospective cohort study must involve patients implanted after registration on the LPPR (List of Products and Services qualifying for Reimbursement). The results of the follow-up study must be forwarded to the National Committee for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) for examination once a year. The assessment of this follow-up could lead to the recommendation by CNEDiMTS to continue or stop the reimbursement of the concerned stent graft. In France, The Valiant Thoracic Stent Graft with the Captivia Delivery System is registered on the LPPR for a period of 3 years since January 12, 2011. In order to comply with HAS expectations, Medtronic Bakken Research Center is setting up this long term non-interventional study on the Valiant Thoracic Stent Graft with the Captivia Delivery System. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Completed |
NCT03665558 -
Effect of Pacing on Aortic dP/dt Values
|
N/A | |
Recruiting |
NCT04149600 -
Identification of Genetic Causes of Calcific Aortic Valve Disease
|
||
Completed |
NCT02876263 -
Noninvasive Neuromonitoring of Surgery of the Thoracic Aorta
|
N/A | |
Recruiting |
NCT03948555 -
Magnetic Resonance Imaging (MRI) for Aortic Dissection to Visualise Inflammation
|
||
Completed |
NCT02266342 -
GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
|
||
Recruiting |
NCT05972018 -
Liposomal Bupivacaine/Bupivacaine in RS Blocks vs. Ropivacaine in RS Blocks And Catheters
|
Phase 4 | |
Completed |
NCT03727542 -
Influence of Short AV Delay Permanent Pacing on Matrix Metalloproteinase Levels
|
N/A | |
Not yet recruiting |
NCT06199401 -
Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery
|
N/A | |
Recruiting |
NCT06358248 -
Standardized Physician-modified Fenestrated Endograft Registry
|
||
Recruiting |
NCT05777681 -
Management of Aorto-iliac Infection With BioIntegral Surgical No-React® Bovine Pericardial Xenografts
|
||
Recruiting |
NCT04995640 -
CILCA Arch Registry: Management and Outcomes of Open and Endovascular Repair
|
||
Recruiting |
NCT05777460 -
Mid- and Long-term Outcomes of Custom-made Aortic Devices
|
||
Not yet recruiting |
NCT05554055 -
Correlation Between LR-ACT and Anti Xa Activity During Endovascular Surgery Procedures. AXAES (Anti Xa vs ACT-LR in Endovascular Surgery)
|
||
Unknown status |
NCT00851149 -
Pro-inflammatory Cytokines in Blood From Orthopedic Surgery Compared to Abdominal Aneurysm Repair
|
N/A | |
Recruiting |
NCT03824626 -
Biomechanical Reappraisal of Planning for Thoracic Endovascular Aortic Repair
|
||
Completed |
NCT02867501 -
Venous Distension in Patients With Aneurysmatic Arterial Disease
|
N/A | |
Completed |
NCT03617601 -
Metabolic Equivalent of Task (MET) in the Preoperative Assessment in Aortic Surgery
|
||
Completed |
NCT01526811 -
Endurantâ„¢ Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms (ENDURANT France)
|
||
Completed |
NCT00538421 -
Opioid-potentiated Volative Anaesthetic Vs. Remifentanil And Propofol During Abdominal Aortic Aneurysm Surgery
|
Phase 4 |